SPH5030

Phase 2Small molecule

SShanghai Pharmaceuticals Holding Co., Ltd

SPH5030 is one of 49 small molecule programs targeting Colorectal Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal CancerRecruiting

HER2-Positive Solid TumorRecruiting

Colorectal CancerPhase 2

Recruiting

HER2-Positive Solid TumorPhase 1

Recruiting

Competition

Competitive Landscape

254 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 3

25 2

Tecentriq

Roche

Phase 3

6 3

Decadron

AAspen Global Incorporated

Phase 3

7 4

Botensilimab

AAgenus Inc.

Phase 3

9 5

5-Fu

TToray Industries, Inc

Phase 3

4 6

Cadonilimab

SShanghai Pharmaceuticals Holding Co., Ltd

Phase 3

2 7

BL-M07D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

1 8

Leucovorin and 5-FU

AAkeso

Phase 3

1 9

Calcium Levofolinate

FFujian Cancer Hospital

Phase 3

1 10

Trodelvy

Gilead

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Colorectal Cancer

NCT06434597

Clinical

Trials by Indication[1]

Colorectal Cancer1 trial

A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.

Recruiting·SShanghai Pharmaceuticals Holding Co., Ltd·Phase 2·NCT06434597·60 enrolled

HER2-Positive Solid Tumor1 trial

SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors

Recruiting·SShanghai Pharmaceuticals Holding Co., Ltd·Phase 1·NCT05245058·150 enrolled

Unspecified1 trial

A Food Effect Study of SPH5030 Tablets.

Completed·SShanghai Pharmaceuticals Holding Co., Ltd·Phase 1·NCT06372223·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for SPH5030. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SPH5030 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SPH5030. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Pharmaceuticals Holding Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShanghai Pharmaceuticals Holding Co., Ltd

SPH5030

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Colorectal Cancer1 trial

HER2-Positive Solid Tumor1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News